[A18-61] Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
Last updated 22.03.2019
Commission awarded on 27.09.2018 by the Federal Joint Committee (G-BA).
Adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
Added benefit not proven for pretreated or treatment-naive patients
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-17||Encorafenib (melanoma) - Addendum to Commission A18-61||Commission completed|
|A20-56||Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|